Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label brentuximab vedotin treatment-option protocol in relapsed or refractory CD30-positive lymphomas
DRKS00010124Phase 2Completed
- Sponsor
- Seagen
- Start
- Mar 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), systemic anaplastic large cell lymphoma (ALCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Seagen. Started Mar 2016; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)systemic anaplastic large cell lymphoma (ALCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on DRKS00010124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010124.